Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new drug aimed at treating prostate cancer, indicating a significant advancement in its product pipeline [1] Group 1: Product Development - HRS-5041 is a novel, efficient, and selective AR-PROTAC small molecule developed by the company [1] - The drug demonstrates significant degradation effects on wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - Currently, there are no similar products approved for market in both domestic and international markets [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for the clinical trial of HRS-5041, a new selective AR-PROTAC small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is designed to effectively degrade androgen receptor (AR) proteins, including various mutant forms, showing significant potential to overcome resistance compared to second-generation AR inhibitors [1] - The total research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a unique position for HRS-5041 in the prostate cancer treatment landscape [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new small molecule aimed at treating prostate cancer [1] Group 1: Product Development - HRS-5041 is a novel, efficient, and selective AR-PROTAC (androgen receptor-protein degradation targeting chimeric) small molecule [1] - The drug demonstrates significant degradation effects on wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - Currently, there are no similar products approved for market in both domestic and international markets [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1]

HRS-5041是公司开发的新型、高效、选择性的AR-PROTAC（雄激素受体-蛋白降解靶向嵌合体）小分 子，拟用于治疗前列腺癌。HRS-5041对野生型及各类突变体的AR蛋白有显著的降解作用，与二代AR 抑制剂相比，有克服耐药的潜力。 格隆汇7月31日丨恒瑞医药(600276.SH)公布，公司及子公司成都盛迪医药有限公司收到国家药品监督管 理局核准签发关于HRS-5041片的《药物临床试验批准通知书》，将于近期开展临床试验。 ...